A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Inclusion Criteria: * Men or women age ≥18 * History of and currently experiencing angina at least 3 times per week * Prior diagnosis of CMD based on coronary flow reserve (CFR) ≤ 2.5 or other measures * Canadian Cardiovascular Society (CCS) class II, III or IV chronic refractory angina * No obstructive coronary artery disease * On stable medical therapy for at least 30 days prior to enrollment * Must agree to use a reliable and acceptable method of contraception for the duration of participation * Written informed consent Exclusion Criteria: * Myocardial infarction within 90 days * Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or CABG) * Diagnosis of other specific cardiac disease * Must meet LVEF and GFR requirements * Current use of coumadin or DOACs * Hypersensitivity to GCSF, apheresis or study product components * Positive for HIV, hepatitis B or hepatitis C * Active inflammatory or autoimmune disease, or chronic immunosuppressive state * Drug abuse * Pregnant or lactating * Malignant neoplasm within 5 years * History of Sickle Cell Disease * Participation in another clinical study within 90 days prior to informed consent or concurrently with this study * Previous treatment with a CD34+ cell based therapy